Jeff Gerth
Jeff Gerth was a senior reporter at ProPublica. Previously, Gerth worked as an investigative reporter at The New York Times. He has twice been awarded the Pulitzer Prize.
Jeff Gerth was a senior reporter at ProPublica. Previously, he worked as an investigative reporter at The New York Times from 1976 through 2005. His work has twice been honored with the Pulitzer Prize. He also won a George Polk Award. His often-prescient coverage has run the gamut from Al Qaeda to Enron, from Whitewater to Chinese technology transfers. During 2004 he was a visiting professor at Princeton University, where he taught an undergraduate seminar on investigative reporting. Gerth is also the co-author (with Don Van Natta Jr.), of Her Way: The Hopes and Ambitions of Hillary Rodham Clinton, published in 2007.
As ISIS Brewed in Iraq, Clinton’s State Department Cut Eyes and Ears on the Ground
An investigation by ProPublica and The Washington Post finds that Secretary of State Clinton initially pressed to keep civilian programs and listening posts after the U.S. troop pullout in 2011, but then her State Department scrapped or slashed them at the behest of the White House and Congress.
by Jeff Gerth,
Hillary Clinton’s Mixed Record on Wall Street Belies Her Tough ‘Cut it Out’ Talk
As a U.S. senator during the crisis years, Clinton’s legislative proposals to reform banking and housing finance didn’t gain traction.
by Jeff Gerth,
Johnson & Johnson Emerges Victorious in Lawsuit on Tylenol’s Risks
Hundreds of cases are pending that involve claims that Tylenol has caused liver damage and deaths. The pain reliever’s maker won a jury verdict in the first.
by Jeff Gerth and T. Christian Miller,
New Trial Records: Doctors Recommended Tylenol — But Only at Lower Doses
Internal company documents that have emerged in a New Jersey trial make clear that marketing for Tylenol did not convey doctors’ concerns about its risks.
by Jeff Gerth and T. Christian Miller,
New Court Docs: Maker of Tylenol Had a Plan to Block Tougher Regulation
Filings from a lawsuit, scheduled to go to trial today in Atlantic City, describe a previously unreported lobbying campaign by McNeil Consumer Healthcare to protect its iconic painkiller.
by Jeff Gerth and T. Christian Miller,
After Years of Study, the FDA Endorses Safety Device for Liquid Children’s Medications
Flow restrictors can help prevent children from taking too much acetaminophen, the active ingredient in Tylenol, which can cause liver damage if taken in high doses.
by T. Christian Miller and Jeff Gerth,
FDA Examines Whether MRI Drugs Accumulate in Brain Tissue
The agency says doctors should consider limiting MRIs to reduce exposure from certain image-enhancing drugs that contain the metal gadolinium.
by Jeff Gerth,
Judges Revive Claim that AT&T Overcharged Schools for Internet Service
A lawsuit can proceed against the company for allegedly failing to offer the required discounts to schools and libraries, says an appeals court.
by Jeff Gerth,
How Much Acetaminophen a Day is Safe? Canada May Decide It’s Less
After an investigation by the Toronto Star, Canada’s top health agency considers whether to lower the maximum recommended daily dose of the active ingredient in Tylenol and other painkillers.
by T. Christian Miller and Jeff Gerth,
Left in the Brain: Potentially Toxic Residue from MRI Drugs
Researchers raise alarms about unknown health risks of GE’s Omniscan and Bayer’s Magnevist, drugs injected to get better MRI pictures that contain the heavy metal gadolinium.
by Jeff Gerth,